Home LiteratureArticle Details
PMID: 11118008 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Mechanism by which metformin reduces glucose production in type 2 diabetes.

Diabetes ·Vol. 49 ·No. 12 ·2000-12-00 ·Pages 2063-9

Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI

Abstract

To examine the mechanism by which metformin lowers endogenous glucose production in type 2 diabetic patients, we studied seven type 2 diabetic subjects, with fasting hyperglycemia (15.5 +/- 1.3 mmol/l), before and after 3 months of metformin treatment. Seven healthy subjects, matched for sex, age, and BMI, served as control subjects. Rates of net hepatic glycogenolysis, estimated by 13C nuclear magnetic resonance spectroscopy, were combined with estimates of contributions to glucose production of gluconeogenesis and glycogenolysis, measured by labeling of blood glucose by 2H from ingested 2H2O. Glucose production was measured using [6,6-2H2]glucose. The rate of glucose production was twice as high in the diabetic subjects as in control subjects (0.70 +/- 0.05 vs. 0.36 +/- 0.03 mmol x m(-2) min(-1), P < 0.0001). Metformin reduced that rate by 24% (to 0.53 +/- 0.03 mmol x m(-2) x min(-1), P = 0.0009) and fasting plasma glucose concentration by 30% (to 10.8 +/- 0.9 mmol/l, P = 0.0002). The rate of gluconeogenesis was three times higher in the diabetic subjects than in the control subjects (0.59 +/- 0.03 vs. 0.18 +/- 0.03 mmol x m(-2) min(-1) and metformin reduced that rate by 36% (to 0.38 +/- 0.03 mmol x m(-2) x min(-1), P = 0.01). By the 2H2O method, there was a twofold increase in rates of gluconeogenesis in diabetic subjects (0.42 +/- 0.04 mmol m(-2) x min(-1), which decreased by 33% after metformin treatment (0.28 +/- 0.03 mmol x m(-2) x min(-1), P = 0.0002). There was no glycogen cycling in the control subjects, but in the diabetic subjects, glycogen cycling contributed to 25% of glucose production and explains the differences between the two methods used. In conclusion, patients with poorly controlled type 2 diabetes have increased rates of endogenous glucose production, which can be attributed to increased rates of gluconeogenesis. Metformin lowered the rate of glucose production in these patients through a reduction in gluconeogenesis.

MeSH Terms
Calorimetry, Indirect Diabetes Mellitus, Type 2/diagnosis,drug therapy,metabolism Female Gluconeogenesis/drug effects,physiology Glucose/antagonists & inhibitors,biosynthesis,metabolism Glycogen/metabolism Humans Hypoglycemic Agents/therapeutic use Liver/metabolism Magnetic Resonance Spectroscopy Male Metformin/therapeutic use Middle Aged
Chemicals
Hypoglycemic Agents Glycogen Metformin Glucose
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Hundal R S
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Krssak M
Dufour S
Laurent D
Lebon V
Chandramouli V
Inzucchi S E
Schumann W C
Petersen K F
Landau B R
Shulman G I
References (38)
38 references, click to expand
  1. Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM.
    Diabetes. 1994 Dec;43(12):1440-4 PMID: 7958496
  2. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
    N Engl J Med. 1998 Mar 26;338(13):867-72 PMID: 9516221
  3. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Ann Intern Med. 1998 Feb 1;128(3):176-85 PMID: 9454525
  4. Direct analysis of 18 O in glucose by mass spectrometry.
    Biochim Biophys Acta. 1973 Feb 28;297(2):213-9 PMID: 4705462
  5. Splanchnic and leg exchange of glucose, amino acids, and free fatty acids during exercise in diabetes mellitus.
    J Clin Invest. 1975 Jun;55(6):1303-14 PMID: 1133176
  6. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus.
    J Clin Invest. 1981 Oct;68(4):957-69 PMID: 7287908
  7. A microfluorometric method for the determination of free fatty acids in plasma.
    J Lipid Res. 1983 Jan;24(1):96-9 PMID: 6833886
  8. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.
    Diabetes. 1988 Jun;37(6):667-87 PMID: 3289989
  9. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy.
    N Engl J Med. 1990 Jan 25;322(4):223-8 PMID: 2403659
  10. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients.
    Diabetes Care. 1990 Jan;13(1):1-8 PMID: 2404714
  11. Quantitative comparison of pathways of hepatic glycogen repletion in fed and fasted humans.
    Am J Physiol. 1990 Sep;259(3 Pt 1):E335-41 PMID: 2205106
  12. In vivo evidence for hepatic autoregulation during FFA-stimulated gluconeogenesis in normal humans.
    Am J Physiol. 1991 Oct;261(4 Pt 1):E425-9 PMID: 1928334
  13. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR.
    Science. 1991 Oct 25;254(5031):573-6 PMID: 1948033
  14. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
    J Clin Endocrinol Metab. 1991 Dec;73(6):1294-301 PMID: 1955512
  15. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control.
    J Clin Endocrinol Metab. 1992 May;74(5):1020-6 PMID: 1569149
  16. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study.
    J Clin Invest. 1992 Oct;90(4):1323-7 PMID: 1401068
  17. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes.
    Eur J Biochem. 1993 May 1;213(3):1341-8 PMID: 8504825
  18. Liver glycogen turnover in fed and fasted humans.
    Am J Physiol. 1994 May;266(5 Pt 1):E796-803 PMID: 8203517
  19. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production.
    Diabetes. 1994 Jul;43(7):920-8 PMID: 8013758
  20. Validation of 13C NMR measurements of liver glycogen in vivo.
    Magn Reson Med. 1994 Jun;31(6):583-8 PMID: 8057810
  21. Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans.
    J Clin Invest. 1998 Mar 15;101(6):1203-9 PMID: 9502760
  22. Use of 2H2O for estimating rates of gluconeogenesis. Application to the fasted state.
    J Clin Invest. 1995 Jan;95(1):172-8 PMID: 7814612
  23. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
    N Engl J Med. 1995 Aug 31;333(9):541-9 PMID: 7623902
  24. Limitations of the mass isotopomer distribution analysis of glucose to study gluconeogenesis. Heterogeneity of glucose labeling in incubated hepatocytes.
    J Biol Chem. 1998 Jul 3;273(27):16853-9 PMID: 9642245
  25. Contributions of net hepatic glycogenolysis and gluconeogenesis to glucose production in cirrhosis.
    Am J Physiol. 1999 Mar;276(3 Pt 1):E529-35 PMID: 10070020
  26. Central role of the adipocyte in insulin resistance.
    J Basic Clin Physiol Pharmacol. 1998;9(2-4):205-21 PMID: 10212835
  27. Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin.
    Diabetes. 1999 Jun;48(6):1251-7 PMID: 10342812
  28. A critical evaluation of mass isotopomer distribution analysis of gluconeogenesis in vivo.
    Am J Physiol. 1999 Jul;277(1 Pt 1):E154-60 PMID: 10409139
  29. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
    N Engl J Med. 1995 Aug 31;333(9):550-4 PMID: 7623903
  30. A limitation in the use of mass isotopomer distributions to measure gluconeogenesis in fasting humans.
    Am J Physiol. 1995 Jul;269(1 Pt 1):E18-26 PMID: 7631774
  31. Limitations of the mass isotopomer distribution analysis of glucose to study gluconeogenesis. Substrate cycling between glycerol and triose phosphates in liver.
    J Biol Chem. 1995 Aug 25;270(34):19806-15 PMID: 7649990
  32. Metformin.
    N Engl J Med. 1996 Feb 29;334(9):574-9 PMID: 8569826
  33. The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans.
    J Clin Invest. 1996 Feb 1;97(3):642-8 PMID: 8609218
  34. Contributions of gluconeogenesis to glucose production in the fasted state.
    J Clin Invest. 1996 Jul 15;98(2):378-85 PMID: 8755648
  35. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
    J Clin Endocrinol Metab. 1996 Nov;81(11):4059-67 PMID: 8923861
  36. The role of fatty acids in mediating the effects of peripheral insulin on hepatic glucose production in the conscious dog.
    Diabetes. 1997 Feb;46(2):187-96 PMID: 9000693
  37. Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver.
    Diabetes. 1997 Sep;46(9):1406-13 PMID: 9287039
  38. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.
    Am J Med. 1997 Dec;103(6):491-7 PMID: 9428832
Article Info
Journal
Diabetes
Abbr.
Diabetes
ISSN
0012-1797
Published
2000-12-00
Pages
2063-9
Language
English
Region
United States
NLM ID
0372763
PMCID
PMC2995498
Subset
IM
Grants
NIDDK NIH HHS · R01 DK014507 · United States
NIDDK NIH HHS · R01 DK049230 · United States
NIDDK NIH HHS · P30 DK-45735 · United States
NIDDK NIH HHS · R01 DK-14507 · United States
NIDDK NIH HHS · P30 DK045735 · United States
NIDDK NIH HHS · K23 DK002734 · United States
NIDDK NIH HHS · K23 DK002734-01 · United States
NIDDK NIH HHS · R01 DK-49230 · United States
NCRR NIH HHS · M01 RR000125 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]